Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: margie who wrote (5510)	10/16/1998 4:00:00 PM
From: sam	Read Replies (1) \| Respond to of 6136

"IMO, the price drop is more related to options expiration and manipulation. Someone may just want to give the shorts another chance to cover, imo." Maybe its Tiger Management deciding its easier to strangle AGPH again than play the Yen/dollar spread.

To: margie who wrote (5510)	10/16/1998 5:13:00 PM
From: Oliver & Co	Respond to of 6136

<From: atp.org.uk Beckerman has “tended to recommend nelfinavir (Viracept) in pregnancy because of timing of meals, worry about kidney stones in mothers and not knowing if the elevated bilirubin in adults might mean some liver toxicity for a fetus, but it is mostly instinct until we have trials."> I have a patient with AIDS, who got pregnant while on Combivir/Viracept, she was kept on this regimen (treated at UM High Risk Pregnancy Clinic by MaryJo O'Sullivan, M.D.) not only was the baby born without HIV or other complications, the mother's health only kept on improving. JLL